Synthesis, Structure−Activity Relationship, and Evaluation of SR141716 Analogues: Development of Central Cannabinoid Receptor Ligands with Lower Lipophilicity

Citations Over TimeTop 10% of 2003 papers

Abstract

Exploration of the central CB1 cannabinoid receptors using positron emission tomography (PET) will allow for an understanding of the pharmacological and physiological role played by these receptors in the CNS. Current tracers are highly lipophilic compounds that exhibit very high nonspecific to specific binding ratios and as a result are inapt for use in humans. We have synthesized a series of less lipophilic analogues of SR141716 to serve as potential radioligands. Binding affinities of the series and a functional electrophysiological assay of three of our compounds have been presented.

Related Papers

• → CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents(2004)241 cited
• → Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes(2002)101 cited
• → Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles(1992)141 cited
• → Cannabinoid–improgan cross-tolerance: Improgan is a cannabinomimetic analgesic lacking affinity at the cannabinoid CB1 receptor(2006)9 cited
• → Cannabinoid Ligand-Receptor Signaling During Early Pregnancy in the Mouse(1999)3 cited